For UK viewers: According to UK ABPI regulations, this symposium is promotional and is intended for healthcare professionals only. Click here for elafibranor▼ UK prescribing and adverse event reporting information.
This symposium was funded by Ipsen.
The primary biliary cholangitis (PBC) management landscape is evolving rapidly, with widening treatment options and growing emphasis on looking beyond biochemistry to address the full burden of disease. This expert discussion, which took place at the European Association for the Study of the Liver (EASL) Congress 2026, held between 27th–30th May, 2026, in Barcelona, Spain, with David Jones, Newcastle University, UK; Marco Carboni, ASST Grande Ospedale Metropolitano Niguarda, Milan, and University of Milano-Bicocca, Italy; and Puneeta Tandon, University of Alberta, Canada, explores how hepatologists can optimise care through proactive risk stratification, treatment decisions, and symptom management.
Watch the symposium to explore:
- Unmet needs in PBC, including early detection of treatment response and comprehensive risk stratification
- How alkaline phosphatase, bilirubin, and liver stiffness inform second-line treatment decisions
- Why the normalisation of biochemistry is becoming a key treatment goal
- The symptomatic burden of PBC, including fatigue and pruritus
Speakers
David Jones1
Marco Carbone2,3
Puneeta Tandon4
1. Faculty of Medical Science, Newcastle University, UK
2. Division of Hepatology and Gastroenterology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
3. University of Milano-Bicocca, Italy
4. Department of Medicine, University of Alberta, Canada
Jones has received honoraria, consultation fees, and speaker fees from Advanz, CymaBay, Falk, GSK, Intercept, Ipsen, and Umecrine; and grant support from Intercept. Carbone has received consultancy or speaker fees from Advanz, Alentis, Albireo, Alfasigma, Amgen, Calliditas, Echosens, Genetic, GSK, Ipsen, Intercept, Kowa, Malesci, Mayoly, Mirum, Perspectum, Umecrine, and Zydus; has been a scientific board advisor for Advanz/Intercept, CymaBay, Falk, Gilead, GSK, Ipsen, Kowa, Mirum, and Moderna; and an investigator for Advanz, Albireo, Amgen, AstraZeneca, Calliditas, Falk, Genkyotex, Gilead, GSK, Mirum, and Roche. Tandon has received consulting fees from Ipsen, Gilead, and Lupin Pharma.
ELA-ALL-002429
